金斯瑞生物科技(01548.HK)：传奇生物旗下CAR-T产品第三季度销售额达5.24亿美元

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate Legend Biotech has reported a net trade sales of approximately $524 million for CARVYKTI® for the quarter ending September 30, 2025, as per the 6-K form submitted to the SEC [1] Group 1: Company Developments - CARVYKTI® is the first CAR-T product from China approved by the FDA [1] - The product was officially approved in the U.S. in March 2022 for the treatment of relapsed or refractory multiple myeloma (R/RMM) patients [1] - CARVYKTI® has also received market approval in the European Union and Japan following its U.S. approval [1]